ClinicalTrials.gg
RecruitingNCT06068387Updated Oct 10, 2023

A Prospective Study on the Prediction Model of Para-aortic Lymph Node Metastasis

An interventional study of surgical staging in Locally Advanced Cervical Cancer, sponsored by Chongqing University Cancer Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-10.

Sponsored by Chongqing University Cancer Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Mar 2023, registered Sep 2023).
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
264
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Uterine Cervical Neoplasms by Chongqing University Cancer Hospital — 13 open to participants now, 13 under way, none of them phase 3. Uterine Cervical Neoplasms · Chongqing University Cancer Hospital.

Planned enrollment
4th of 15
264 · median 60
Started
2023
with 4 others
No phase
9 of 18
8 open now
Primary completion
2025-02
later than 3 of 12 live
Registered
14th of 18
by date

Among the 18 studies in Uterine Cervical Neoplasms by Chongqing University Cancer Hospital, this one is the 4th largest by planned enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2023, is one of 9 with no phase, reaches primary completion later than 3 of the 12 other live ones, and was the 14th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

13 of the 18 studies in Uterine Cervical Neoplasms by Chongqing University Cancer Hospital are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Uterine Cervical Neoplasms by Chongqing University Cancer Hospital, or all of them as a file.
02

Study summary

The goal of this prospective single-arm trial is to investigate the accuracy and feasibility of the para-aortic lymph node metastasis prediction model in locally advanced cervical cancer, as well as its impact on patients' prognosis. The main questions it aims to answer are:

  • Is the para-aortic lymph node metastasis prediction model accurate and feasible?
  • Whether the para-aortic lymph node metastasis prediction model can affect the prognosis of patients.
03

Conditions studied

  • Locally Advanced Cervical Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In 2018, the International Federation of Obstetrics and Gynecology (FIGO) stage was Ib3 IIA2-IVA;
  • It was treated initially without surgical and chemotherapy.
  • Squamous cell carcinoma, adenocarcinoma and adeno-squamous cell carcinoma were confirmed by histopathology.
  • Pelvic MRI ± abdominal CT or MRI or PET/CT were performed before treatment.
  • score:0 \~ 1.
  • The expected survival time>6 months;
  • There is no absolute of surgery and and chemoradiotherapy and the patients with good compliance.

Exclusion criteria

Exclusion Criteria:

  • History of immune disease who need to take drugs.
  • History of serious mental illness and brain functional disorder.
  • Other were diagnosed within five years or needed treatments.
  • Those who are unable or unwilling to accept surgical treatment/sign /comply with research requirements.
  • Without surgical conditions: 1) Chronic renal insufficiency or renal failure; 2) Liver insufficiency; 3)Chronic lung disease with restrictive respiratory dysfunction; 4) Cardiac dysfunction (patients with relative and absolute to surgery after consultation by cardiac physicians.
  • Patients who cannot understand the research regimen and refuse to sign the informed consent form.
  • Other concomitant diseases or special conditions seriously endanger the patient's health or interfere with the trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
264 participants (estimated)

Study arms

  • Experimental
    experimental group

    locally advanced cervical cancer treated with surgical staging

    Procedure: surgical staging

Interventions

  • Proceduresurgical staging

    para-aortic lymphadenectomy from the inferior mesenteric artery cranially to the aorta caudally via laparoscopy or laparotomy

06

What researchers measure

Primary outcomes

  1. The accuracy of the prediction model

    The performance of the model was assessed with respect to discrimination which was measured by the concordance index and calibration which was assessed by the calibration curve, Hosmer-Lemeshow test and Brier score. The investigators will calculate respectively the sensitivity and 95% confidence interval (CI), specificity and 95% CI, positive likelihood ratios (LR+) and 95% CI, negative likelihood ratios (LR-) and 95% CI, and the Kappa value.

    Time frame: 2 years

Secondary outcomes

  1. PFS

    Progression-free Survival

    Time frame: 3 years

  2. LRR

    The local recurrence rate of para-aortic lymphatic drainage area

    Time frame: 1 year

  3. LRR

    The local recurrence rate of para-aortic lymphatic drainage area

    Time frame: 2 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Feb 2025, 23 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 23 months is below that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2023
First posted
Oct 5, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Feb 28, 2025
CompletionEst.
Feb 28, 2026
Last update
Oct 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06068387
Lead sponsor
Chongqing University Cancer Hospital
Responsible party
Dongling Zou (Director, Chongqing University Cancer Hospital) — Principal investigator
First posted
Oct 5, 2023
Start date
Mar 1, 2023
Primary completion
Feb 28, 2025 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Oct 10, 2023

Study contacts

Dongling Zou, M.D.
Contact
cqzl_zdl@163.com
13657690699
Dongling Zou, M.D.
study director · Chongqing University Cancer Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion